News | January 28, 2026
Parse Biosciences unveils integrated immune profiling in Trailmaker Platform
The new functionality complements Parse’s existing Evercode immune products
The new functionality complements Parse’s existing Evercode immune products
TruVerus is the only FDA cleared, multi-modal platform capable of delivering comprehensive routine testing from a single lithium heparin sample
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
Company to launch product after the expiry of semaglutide patent in India
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
Subscribe To Our Newsletter & Stay Updated
